---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008723"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:17:59.190297+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# bioAffinity presents positive data on sputum diagnostics to match asthma/COPD patients with therapies

## Summary
- Poster presented at AAAAI 2026 annual meeting on March 1, 2026, reports ability to identify antibody drug receptors in sputum.
- Technology detected receptors for dupilumab and benralizumab, leading asthma/COPD therapies.
- Company leveraging CyPath® Lung flow cytometry and AI platform for new asthma/COPD diagnostic tests.
- CyPath® Lung commercial test has 92% sensitivity, 87% specificity for early-stage lung cancer detection.

## SEC filing metadata
- accession: 0001493152-26-008723
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226008723/0001493152-26-008723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226008723/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008723
- JSON: https://secwatch.observer/filing/0001493152-26-008723.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008723.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.